Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC

Laura C Coates; Toby Garrood; Nicola Gullick; Philip Helliwell; Toby Kent; Jonathan Marks; William Tillett; Daljit Kaur-Papadakis; Hasan Tahir; Stijn van Haaren; Iain McInnes

doi:10.1093/rheumatology/keac388

Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC

Laura C Coates, Toby Garrood, Nicola Gullick, Philip Helliwell, Toby Kent, Jonathan Marks, William Tillett, Daljit Kaur-Papadakis, Hasan Tahir, Stijn van Haaren, Iain McInnes

Research output: Contribution to journal › Article › peer-review

1 Citation (SciVal)

50 Downloads (Pure)

Original language	English
Article number	keac388
Pages (from-to)	e1-e3
Journal	Rheumatology (Oxford, England)
Volume	62
Issue number	1
Early online date	7 Jul 2022
DOIs	https://doi.org/10.1093/rheumatology/keac388
Publication status	Published - 31 Jan 2023

Bibliographical note

The study was funded by AbbVie Ltd.

Access to Document

10.1093/rheumatology/keac388

PsARC_Letter_to_the_Editor_v1.0_Clean.PDF
This is a pre-copyedited, author-produced version of an article accepted for publication in Rheumatology following peer review. The version of record Laura C Coates, Toby Garrood, Nicola Gullick, Philip Helliwell, Toby Kent, Jonathan Marks, William Tillett, Daljit Kaur-Papadakis, Hasan Tahir, Stijn van Haaren, Iain McInnes, Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC, Rheumatology, 2022;, keac388, is available online at: https://doi.org/10.1093/rheumatology/keac388
Accepted author manuscript, 193 KB

Cite this

Coates, L. C., Garrood, T., Gullick, N., Helliwell, P., Kent, T., Marks, J., Tillett, W., Kaur-Papadakis, D., Tahir, H., van Haaren, S., & McInnes, I. (2023). Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC. Rheumatology (Oxford, England), 62(1), e1-e3. Article keac388. https://doi.org/10.1093/rheumatology/keac388

Coates, LC, Garrood, T, Gullick, N, Helliwell, P, Kent, T, Marks, J, Tillett, W, Kaur-Papadakis, D, Tahir, H, van Haaren, S & McInnes, I 2023, 'Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC', Rheumatology (Oxford, England), vol. 62, no. 1, keac388, pp. e1-e3. https://doi.org/10.1093/rheumatology/keac388

@article{c22442d3034a43e299cfc487802c39fe,

title = "Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC",

author = "Coates, {Laura C} and Toby Garrood and Nicola Gullick and Philip Helliwell and Toby Kent and Jonathan Marks and William Tillett and Daljit Kaur-Papadakis and Hasan Tahir and {van Haaren}, Stijn and Iain McInnes",

note = "The study was funded by AbbVie Ltd.",

year = "2023",

month = jan,

day = "31",

doi = "10.1093/rheumatology/keac388",

language = "English",

volume = "62",

pages = "e1--e3",

journal = "Rheumatology (Oxford, England)",

issn = "1462-0324",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC

AU - Coates, Laura C

AU - Garrood, Toby

AU - Gullick, Nicola

AU - Helliwell, Philip

AU - Kent, Toby

AU - Marks, Jonathan

AU - Tillett, William

AU - Kaur-Papadakis, Daljit

AU - Tahir, Hasan

AU - van Haaren, Stijn

AU - McInnes, Iain

N1 - The study was funded by AbbVie Ltd.

PY - 2023/1/31

Y1 - 2023/1/31

UR - http://www.scopus.com/inward/record.url?scp=85144637374&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/keac388

DO - 10.1093/rheumatology/keac388

M3 - Article

C2 - 35799375

SN - 1462-0324

VL - 62

SP - e1-e3

JO - Rheumatology (Oxford, England)

JF - Rheumatology (Oxford, England)

IS - 1

M1 - keac388

ER -

Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC

Bibliographical note

Access to Document

Other files and links

Outcome Measures for Randomised Controlled Trials in Psoriatic Arthritis

Cite this

Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC

Bibliographical note

Access to Document

Other files and links

Projects

Outcome Measures for Randomised Controlled Trials in Psoriatic Arthritis

Cite this